Rimon Partner Andrew Reilly was recently featured in Lawyers Weekly following a significant U.S. Securities and Exchange Commission (SEC) exemption that reduces duplicate reporting requirements for directors and officers of certain Australian Securities Exchange (ASX)-listed companies that are also listed in the United States. The exemption recognizes that Australia’s existing disclosure framework imposes substantially similar…

A significant number of Australian and New Zealand issuers accessed the US capital markets in 2025. We have identified 134 US debt and equity offers that were completed by Australian and New Zealand issuers in 2025, with a median amount raised of A$60 million. The following graph shows the number of debt and equity offers…

We are pleased to congratulate Sean Byrne, Nicolas Lafont, Andrew Reilly, and Richard Ernest on being recognized in the 2025 edition of IFLR1000. This year’s guide includes Sean Byrne and Nicolas Lafont as Notable Practitioners, while Richard Ernest and Andrew Reilly were recognized as Highly Regarded. Research Methodology: IFLR1000 evaluates law firms and lawyers by…

We congratulate our client, Neuphoria Therapeutics Inc. on their successful redomiciliation to the U.S. In celebratory fashion, Neuphoria Therapeutics Inc. rang the Nasdaq Opening Bell on March 3rd, 2025!  Ted Ghorra, Andrew Reilly, Elaine Wangsawidjaja and Olivia Wang have worked regularly with this client. Read more here Rimon’s Securities and Capital Markets attorneys have decades…

A significant number of Australian and New Zealand issuers accessed the US capital markets in 2024. We have identified 145 US debt and equity offers that were completed by Australian and New Zealand issuers in 2024, with a median amount raised of A$100 million. The following graph shows the number of debt and equity offers…

Rimon is proud to have acted as US counsel to Bionomics Limited, an Australian clinical-stage biotechnology company, on its re-domiciliation to the United States and the successful listing of its new Delaware parent company (Neuphoria Therapeutics Inc.) on Nasdaq. Such a re-domiciliation involves an Australian statutory scheme of arrangement under which, following approval by shareholders…

We are pleased to announce the proposed business combination agreement between Rimon client, Australian Food & Agriculture Company Limited (AF&A), and Agriculture & Natural Solutions Acquisition Corporation, a special purpose acquisition company. Upon closing, the combined company, Agriculture & Natural Solutions Company Limited (“NewCo”), expects to be listed on the New York Stock Exchange (NYSE)…

Commencing January 2024, millions of companies must report beneficial ownership information (BOI) to the US Treasury’s Financial Crimes Enforcement Network (FinCEN) pursuant to the US Corporate Transparency Act (the CTA). The CTA was enacted to deter money laundering, financing of terrorism, tax fraud and other illegal acts by increasing transparency surrounding the control and ownership…

A significant number of Australian and New Zealand issuers accessed the US capital markets in 2023. We have identified 128 US debt and equity offers that were completed by Australian and New Zealand issuers in 2023, with a median amount raised of A$100 million. The following graph shows the number of debt and equity offers…

Rimon Law has acted as US counsel to Incannex Healthcare Limited, an ASX-listed Australian clinical stage company that is developing medicinal cannabis pharmaceutical products and psychedelic medicine therapies, on its re-domiciliation to Delaware with a listing on Nasdaq. Such a re-domiciliation involves an Australian statutory scheme of arrangement under which, following approval by shareholders and…